No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer drug Etcamah (camizestrant), used alongside a CDK4/6 inhibitor, has been granted accelerated approval in the US for patients with a common form of advanced breast cancer who show signs of developing resistance to standard hormone therapy.
AstraZeneca said the decision was based on an FDAauthorised blood test that detects emerging ESR1 mutations, which signal that current treatment was becoming less effective and follows results from its Phase III SERENA6 trial.
In an interim analysis, the Etcamah combination cut the risk of disease progression or death by 56% compared with continuing aromataseinhibitor therapy, extending median progressionfree survival to 16 months from 9.2 months. A later planned analysis showed a meaningful improvement in time to second progression, while overallsurvival data continued to trend in favour of the regimen.
The FTSE 100-listed firm said the safety profile of Etcamah used with palbociclib, ribociclib or abemaciclib was in line with expectations, with no new concerns identified and low discontinuation rates.
AstraZeneca added that alongside the drug approval, the FDA also cleared a companion diagnostic designed to detect ESR1 mutations through circulating tumour DNA.
As of 0845 BST, AstraZeneca shares were up 0.70% at 12,090p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.